Spectral Diagnostics (EDTXF) Stock Price, News & Analysis

Company Overview

Spectral Diagnostics, now known as Spectral Medical Inc., is a Canadian medical-device and biotechnology company focused on products for the diagnosis and treatment of sepsis and septic shock. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and can contribute to severe systemic inflammation.

Spectral’s primary diagnostic product is the Endotoxin Activity Assay (EAA), a blood test designed to measure a patient’s endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis. The assay is intended to support physicians in assessing patients and selecting potential treatment strategies.

The company has also been involved in the development and commercialization of blood-purification therapies, including polymyxin B hemoperfusion, which is designed to remove endotoxins from the bloodstream. Spectral Medical serves the critical-care and hospital markets, with operations and commercial activities focused primarily in North America and other international markets through regulatory and distribution relationships.

Key Stats

• Today's Range: $0.81 to $0.82
• 50-Day Range: $0.76 to $1.02
• 52-Week Range: $0.65 to $1.15
• Volume: 2,600 shs
• Average Volume: 13,436 shs
• Market Capitalization: $239.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Spectral Diagnostics Stock Analysis - MarketRank™

Spectral Diagnostics scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Spectral Diagnostics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Spectral Diagnostics is -8.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spectral Diagnostics is -8.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Spectral Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Spectral Diagnostics has a short interest ratio ("days to cover") of 0.55, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spectral Diagnostics has recently decreased by 39.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spectral Diagnostics does not currently pay a dividend.

Dividend Growth

Spectral Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Spectral Diagnostics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Spectral Diagnostics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spectral Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Spectral Diagnostics is held by insiders.

Percentage Held by Institutions

Spectral Diagnostics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:EDTXF
• Previous Symbol: OTCMKTS:DIAGF
• CIK: N/A
• Web: www.spectraldx.com
• Phone: (416) 626-3233
• Fax: 416-626-7383
• Employees: 29
• Year Founded: 1991

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.13 million
• Net Margins: -1,393.13%
• Pretax Margin: -1,387.92%
• Return on Equity: N/A
• Return on Assets: -652.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.04
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: $1.75 million
• Price / Sales: 136.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.17) per share
• Price / Book: -4.78

Miscellaneous

• Outstanding Shares: 294,640,000
• Free Float: 290,221,000
• Market Cap: $239.37 million
• Optionable: Not Optionable
• Beta: 0.16